

The Role of Alkalinisation Therapy in Tricyclic Antidepressant Toxicity

Mr. Kieran Pai

A/Prof. Betty Chan
Dr. Angela Chiew
Prof. Nicholas Buckley
Dr. Therese Becker
Dr. Katherine Isoardi
Dr. Rose Cairns
Mr. Jared Brown



NSW
poisons Information Centre
the children's hospital at Westmead


13 11 26

NHS
The Princess Alexandra
Hospital
NHS Trust







Epidemiology

Tricyclic Antidepressant (TCA) poisonings


- TCAs have a relatively high toxicity profile
- No longer first-line treatment for depression
- Remain indicated in resistant depression
- During 2017 in the USA alone:
 - ~10,000 recorded cases
 - 73 reported fatalities
 - 2.2% of all poisoning-related mortalities



Pathophysiology

	Normal patient	TCA toxicity
Cardiac sodium channel		
Cardiac Action Potential		
ECG		
Legend	● = Sodium ion (Na ⁺) ▽ = free TCA	

Treatment



Gaps in the Literature

- Few studies support the need for therapeutic hyperventilation
- No study has quantified the effects of NaHCO_3 and hyperventilation on the biochemical profile
- Little evidence demonstrating therapeutic effects of NaHCO_3 and/or hyperventilation in humans
- Lack of guidelines for dosing NaHCO_3 and regulating hyperventilation





Objectives




To quantify the effects of NaHCO_3 and hyperventilation on:

- The biochemical profile (serum pH, $[\text{Na}^+]$)
- ECG findings (QRS interval)



To test how accurately our mathematical model can predict increases in serum pH




To use our model to develop a nomogram for the dosage of NaHCO_3 and regulation of hyperventilation

Methods




- 7 year retrospective review
- Patients ≥ 15 yo with ≥ 10 mg/kg TCA overdose
- Nation-wide
 - South Eastern Area Toxicology Service (SEATS)
 - Princess Alexandra Toxicology Service (PATs)
 - NSW Poisons Information Centre (PIC)
- Recorded serial blood gases and ECG
- Widened QRS is >110 msec. Therapeutic narrowing of QRS if decrease by >30 msec or to <100 msec

Overview of Results




Serum Alkalinisation



NaHCO₃ and hyperventilation worked best

...but further guidelines are required

Loading Serum Sodium with NaHCO_3




100-400mmol of NaHCO_3 seems appropriate for sodium loading

...but doses above 400mmol may risk hyponatremia

NaHCO₃ and hyperventilation and QRS narrowing

- QRS narrowing occurred **3x sooner** in the **dual therapy** group (n=51) compared to the **single/supportive therapy** group (n=33)
 - Cox regression: OR: 3.2, 95%CI: 1.2-8.2, p=0.02




Predicting increases in pH following treatment

Predicting Serum pH:

$$[\text{serum } \text{HCO}_3^-]_{\text{after Tx}} = [\text{serum } \text{HCO}_3^-]_{\text{before Tx}} + \frac{\text{NaHCO}_3}{40} + 0.2 \times \Delta \text{PCO}_2$$

Using the Henderson-Hasselbalch equation:

$$\text{pH}_{\text{after Tx}} = 6.1 + \log \left(\frac{[\text{serum } \text{HCO}_3^-]_{\text{after Tx}}}{0.03 \times \text{PCO}_2 \text{ after Tx}} \right)$$




Accuracy of Equation

Intraclass correlation coefficient (ICC) - a measure of accuracy

0 = no accuracy, 1 = perfect accuracy

Serum pH:

ICC = 0.84 (95%CI: 0.77-0.90)




A nomogram for dosing NaHCO_3

Patient example:

- PCO_2 50mmHg
- Serum pH 7.25
- Recommended NaHCO_3 dose:
200-250mmol

The nomogram:

- Aims to increase pH to 7.50
- Assumes hyperventilation to
 PCO_2 30mmHg
- Caution with $\text{NaHCO}_3 \geq 500\text{mmol}$



Conclusion

- Alkalinisation therapy is best achieved through **both NaHCO_3 and hyperventilation**
- These therapies can help **narrow QRS**
- We recommend hyperventilating patients to **PCO_2 30mmHg** and dosing NaHCO_3 according to our **nomogram**
- Caution should be applied with doses of NaHCO_3 beyond **400mmol**
- Therapy should be ceased if serum pH **>7.55** or if serum $[\text{Na}^+]$ increases by **>10mmol/L**

Questions?



Limitations and future directions

Limitations

Retrospective study:

- Incomplete or erroneous documentation
- Confounding treatments
- Non-uniform methods of measurement

Limited findings:

- Could not demonstrate therapeutic effects of treatments apart from QRS narrowing

Future directions

Prospective study (SODA 2):

- Uniform approach to treatment and observation
- Can assess benefits of treatment guidelines

Larger study:

- Investigate how other ECG markers (e.g. avR or R/S ratio) or clinical signs (e.g. hypotension) are affected by these treatments
- More standardised measurements (before AND after treatment)

Overview of Results

	NaHCO ₃ group (IQR) n=86	No NaHCO ₃ group (IQR) n=74	P-value
Dose of NaHCO ₃	200 (100-300)	0	
Age	44 (28-57)	43 (27-51)	ns
Female	51 (59%)	52 (70%)	ns
Dose (g)	1.5 (1.3-2.5)	1.3 (1.0-1.8)	0.0010
Maximum HR (bpm)	124 (102-133)	105 (96-120)	0.0006
Minimum MAP (mmHg)	72 (65-84)	77 (70-89)	0.0159
Minimum GCS	3 (3-8)	10 (3-13)	<0.0001
Intubated	74 (86%)	32 (43%)	<0.0001
Maximum QRS (msec)	122 (108-138)	105 (94-115)	<0.0001
Length of stay	2.0 (1.3-2.7)	1.0 (0.6-1.8)	<0.0001
Seizure	11 (13%)	3 (4%)	ns
Death	1 (1%)	0	ns

Rules of thumb

Every 10mmHg decrease in PCO_2 increases serum pH by approximately 0.05

Every 100mmol of NaHCO_3 increases pH by approximately 0.05

ICC: 0.80 (95%CI: 0.71-0.87)



- Clinically simple to remember and implement
- Does not require nomogram's conditions



- Less accurate than Henderson-Hasselbalch equation
- pH change varies with patient biochemistry (HCO_3^- and PCO_2)

Mathematics behind nomogram

Assume final pH = 7.50, final PCO ₂ =30mmHg. Sub into H-H equation	$7.5 = 6.1 + \log \left(\frac{[\text{serum } HCO_3^-]_{\text{after } Tx}}{0.03 \times 30} \right) \rightarrow [\text{Serum } HCO_3^-]_{\text{after } Tx} = 22.6 \text{ mmol/L}$
From our equations:	$[\text{serum } HCO_3^-]_{\text{after } Tx} = [\text{serum } HCO_3^-]_{\text{before } Tx} + \frac{NaHCO_3}{40} + 0.2 \times \Delta PCO_2$
Rearranging Henderson-Hasselbalch equation:	$[\text{serum } HCO_3^-]_{\text{before } Tx} = 10^{pH_{\text{before } Tx} - 6.1} \times 0.03 \times PCO_{2\text{before } Tx}$
Y-axis is PCO ₂ on assessment and x-axis is recommended dose of NaHCO ₃ . Substituting previous:	$22.6 = 10^{pH_{\text{before } Tx} - 6.1} \times 0.03 \times y + \frac{x}{40} + 0.2(30 - y)$
Rearrange for y:	$y = \frac{x - 664}{8 - 1.2 \times 10^{pH_{\text{before } Tx} - 6.1}}$
Substitute pH (e.g. 7.25)	$y = \frac{x - 664}{-9.0}$

Bland-Altman Analysis

